Kyverna Therapeutics, Inc. (KYTX)
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$161.3M
- Total assets
- $293.8M
- Market cap
- $454.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $169.8M
- Operating income
- -$169.8M
- Income tax
- $0
- Net income
- -$161.3M
- EPS (basic)
- $-3.64
- EPS (diluted)
- $-3.64
Balance sheet
- Total assets
- $293.8M
- Current assets
- $283.0M
- Total liabilities
- $61.5M
- Current liabilities
- $36.5M
- Shareholders’ equity
- $232.3M
Cash flow
- Operating cash flow
- -$153.7M
- Investing cash flow
- $40.0M
- Financing cash flow
- $141.2M
- Net cash flow
- $27.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $454.1M
- EPS (diluted)
- $-3.64
- Shares outstanding
- 61.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 8, 2024
Kyverna Therapeutics, Inc. (KYTX) Stock Price
- Reported a net loss of $161.3M.
- Trading 34% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Kyverna Therapeutics, Inc..
Write a review
News about Kyverna Therapeutics, Inc.
News & sentiment via Polygon.io
Kyverna Therapeutics, Inc.: frequently asked questions
Is Kyverna Therapeutics, Inc. an American company?
Kyverna Therapeutics, Inc. is a US-based company headquartered in Emeryville, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Kyverna Therapeutics, Inc. headquartered?
Kyverna Therapeutics, Inc. is headquartered in Emeryville, California, United States.
Is Kyverna Therapeutics, Inc. publicly traded?
Yes — Kyverna Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol KYTX on the NASDAQ.
What does Kyverna Therapeutics, Inc. do?
Kyverna Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
